"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 6 | 8 |
| 1996 | 2 | 9 | 11 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 2 | 2 | 4 |
| 2001 | 4 | 2 | 6 |
| 2002 | 4 | 4 | 8 |
| 2003 | 3 | 6 | 9 |
| 2004 | 2 | 3 | 5 |
| 2005 | 0 | 10 | 10 |
| 2006 | 3 | 4 | 7 |
| 2007 | 6 | 4 | 10 |
| 2008 | 7 | 10 | 17 |
| 2009 | 5 | 10 | 15 |
| 2010 | 6 | 1 | 7 |
| 2011 | 14 | 5 | 19 |
| 2012 | 5 | 4 | 9 |
| 2013 | 4 | 1 | 5 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 6 | 9 |
| 2016 | 7 | 4 | 11 |
| 2017 | 10 | 4 | 14 |
| 2018 | 3 | 4 | 7 |
| 2019 | 7 | 1 | 8 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 6 | 8 |
| 2022 | 2 | 3 | 5 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr; 39(4):942-950.
-
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials. J Crohns Colitis. 2025 Feb 04; 19(2).
-
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar; 39(3):710-719.
-
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 2024 Dec; 25(12):1576-1588.
-
Enhanced Payload Localization in Antibody-Drug Conjugates Using a Middle-Down Mass Spectrometry Approach with Proton Transfer Charge Reduction. Anal Chem. 2024 Nov 19; 96(46):18483-18490.
-
Liver Pathology Related to Onco-Therapeutic Agents. Surg Pathol Clin. 2023 Sep; 16(3):499-518.
-
Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Paediatr Drugs. 2022 Nov; 24(6):699-714.
-
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
-
A pyrosequencing protocol for rapid identification of SARS-CoV-2 variants. J Med Virol. 2022 08; 94(8):3661-3668.
-
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 Mar 01; 28(5):882-892.